Cadinha & Co. LLC Has $22 Million Holdings in Johnson & Johnson (JNJ)
Cadinha & Co. LLC raised its stake in Johnson & Johnson (NYSE:JNJ) by 0.5% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 166,311 shares of the company’s stock after buying an additional 890 shares during the quarter. Johnson & Johnson makes up approximately 3.8% of Cadinha & Co. LLC’s investment portfolio, making the stock its 5th largest position. Cadinha & Co. LLC’s holdings in Johnson & Johnson were worth $22,001,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors also recently modified their holdings of the business. State Street Corp grew its holdings in shares of Johnson & Johnson by 4.3% during the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after purchasing an additional 6,656,371 shares during the period. Schwab Charles Investment Management Inc. grew its holdings in shares of Johnson & Johnson by 4.2% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 11,623,639 shares of the company’s stock worth $1,537,692,000 after purchasing an additional 473,300 shares during the period. Fisher Asset Management LLC grew its holdings in shares of Johnson & Johnson by 3.7% during the 2nd quarter. Fisher Asset Management LLC now owns 11,499,415 shares of the company’s stock worth $1,521,258,000 after purchasing an additional 405,517 shares during the period. Clearbridge Investments LLC grew its holdings in shares of Johnson & Johnson by 3.4% during the 1st quarter. Clearbridge Investments LLC now owns 9,543,827 shares of the company’s stock worth $1,188,684,000 after purchasing an additional 310,831 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. grew its holdings in shares of Johnson & Johnson by 0.5% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,948,942 shares of the company’s stock worth $990,041,000 after purchasing an additional 42,144 shares during the period. Institutional investors own 65.61% of the company’s stock.
A number of equities analysts have recently weighed in on JNJ shares. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $148.00 price target for the company in a report on Thursday, July 27th. Credit Suisse Group reiterated a “buy” rating on shares of Johnson & Johnson in a report on Friday, August 4th. J P Morgan Chase & Co increased their price target on Johnson & Johnson from $140.00 to $148.00 and gave the stock an “overweight” rating in a report on Wednesday, August 16th. Jefferies Group LLC set a $145.00 price target on Johnson & Johnson and gave the stock a “hold” rating in a report on Tuesday, August 15th. Finally, Cowen and Company set a $147.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a report on Thursday, August 24th. Four equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the stock. Johnson & Johnson presently has an average rating of “Hold” and a consensus target price of $143.70.
Shares of Johnson & Johnson (NYSE:JNJ) opened at $137.29 on Thursday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. The stock has a market capitalization of $371,653.16, a PE ratio of 19.38, a price-to-earnings-growth ratio of 2.81 and a beta of 0.82. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $144.35.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. The company had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. Johnson & Johnson’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the company earned $1.68 EPS. equities research analysts expect that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.45%. The ex-dividend date of this dividend is Monday, November 27th. Johnson & Johnson’s dividend payout ratio is currently 58.33%.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.